30 December 2020 - In July, the nation implemented a “tiered system” to restructure the drug-pricing method, which called for differentiating drug prices to keep generic medicines from recklessly rushing into the market.

This system sets different drug prices depending on bioequivalence studies' performance and the use of substances registered in the drug master file. The prices of generic drugs that meet both qualifications are set at 53.55% of the original drug price. In comparison, products that satisfy only one condition are priced at 45.52%. 

Those without any qualification are fixed at 38.69% of the original drug’s price.

Read Korea Biomedical Review article